Single nucleotide polymorphisms in the apolipoprotein B and low density lipoprotein receptor genes affect response to antihypertensive treatment
1 Department of Medical Sciences, Uppsala University, Uppsala University Hospital, Entrance 70, 3rd floor, 751 85 Uppsala, Sweden
2 Uppsala Clinical Research Center (UCR), Uppsala University, 751 85 Uppsala, Sweden
3 Division of Internal Medicine, Karolinska Institute, Danderyd Hospital, 182 88 Stockholm, Sweden
4 Astra Zeneca Research & Development Mölndal, 431 83 Mölndal, Sweden
BMC Cardiovascular Disorders 2004, 4:16 doi:10.1186/1471-2261-4-16Published: 28 September 2004
Dyslipidemia has been associated with hypertension. The present study explored if polymorphisms in genes encoding proteins in lipid metabolism could be used as predictors for the individual response to antihypertensive treatment.
Ten single nucleotide polymorphisms (SNP) in genes related to lipid metabolism were analysed by a microarray based minisequencing system in DNA samples from ninety-seven hypertensive subjects randomised to treatment with either 150 mg of the angiotensin II type 1 receptor blocker irbesartan or 50 mg of the β1-adrenergic receptor blocker atenolol for twelve weeks.
The reduction in blood pressure was similar in both treatment groups. The SNP C711T in the apolipoprotein B gene was associated with the blood pressure response to irbesartan with an average reduction of 19 mmHg in the individuals carrying the C-allele, but not to atenolol. The C16730T polymorphism in the low density lipoprotein receptor gene predicted the change in systolic blood pressure in the atenolol group with an average reduction of 14 mmHg in the individuals carrying the C-allele.
Polymorphisms in genes encoding proteins in the lipid metabolism are associated with the response to antihypertensive treatment in a drug specific pattern. These results highlight the potential use of pharmacogenetics as a guide for individualised antihypertensive treatment, and also the role of lipids in blood pressure control.